go back

Brexucabtagene Autoleucel (Tecartus) CAR-T Therapy

Alabama rates for HCPCS Q2053

Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $79,433 · 10th–90th $61,660$489,7790%10%20%10th90th$79,433Professionalmedian $489,779 · 10th–90th $489,779$512,8610%50%90th$489,779$50.0K$100.0K$200.0K$500.0K$1.0M

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Need provider-level prices? Contact us.

Insurance Carrier
Aetna
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$512,861.38
BCBS
Setting
Facility
Modifier
Global
Typical Low
$61,659.50
Median
$74,131.02
Typical High
$100,000.00
Cigna
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$588,843.66
United
Setting
Facility
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$512,861.38
United
Setting
Professional
Modifier
Global
Typical Low
$363,078.05
Median
$467,735.14
Typical High
$549,540.87